|
|||||
|
|
LMP-420, a small-molecule inhibitor of TNF-alpha, reduces replication of HIV-1 and Mycobacterium tuberculosis in human cells |
|
| Authors: | Soichi Haraguchi Noorbibi K Day Wasu Kamchaisatian Macarena Beigier-Pompadre Steffen Stenger Nutthapong Tangsinmankong John W Sleasman Salvatore V Pizzo George J Cianciolo |
| Affiliation: | 1. Department of Pediatrics, University of South Florida, 801 Sixth Street South, St. Petersburg, FL, 33701, USA 2. Institut für Klinische Mikrobiologie, Immunologie und Hygiene der Friedrich-Alexander Universit?t Erlangen-Nürnberg, Erlangen, Germany 3. Department of Pathology, Duke University Medical Center, Durham, NC, 27710, USA |
| Abstract: | BackgroundCo-infections of human immunodeficiency virus (HIV) and Mycobacterium tuberculosis (M. Tb) are steadily increasing and represent a major health crisis in many developing countries. Both pathogens individually stimulate tumor necrosis factor-alpha (TNF) release from infected cells and TNF, in turn, enhances the replication of each. A recent report on a Phase I clinical trial suggested that etanercept (soluble TNF receptor) might be beneficial in treating HIV/M. Tb co-infected patients. We sought to determine if a small molecule inhibitor of TNF synthesis and activity could block replication of either organism and thus be a potential adjunct to existing drugs targeting these agents. |
| Keywords: | |
| 本文献已被 SpringerLink 等数据库收录！ | |